Foundation Medicine Inc (NASDAQ:FMI) insider Vincent A. Miller sold 32,008 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $76.87, for a total value of $2,460,454.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Foundation Medicine Inc (NASDAQ FMI) traded down $2.00 during trading on Friday, reaching $73.75. The company had a trading volume of 128,200 shares, compared to its average volume of 262,067. The stock has a market cap of $2,746.13, a PE ratio of -16.86 and a beta of -0.03. Foundation Medicine Inc has a 1 year low of $22.75 and a 1 year high of $78.59. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47.
A number of institutional investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC acquired a new stake in Foundation Medicine in the 4th quarter worth about $488,000. Castleark Management LLC acquired a new stake in Foundation Medicine in the 4th quarter worth about $1,333,000. Financial Advocates Investment Management acquired a new stake in Foundation Medicine in the 4th quarter worth about $239,000. Millennium Management LLC acquired a new stake in Foundation Medicine in the 4th quarter worth about $1,777,000. Finally, Raymond James & Associates acquired a new stake in Foundation Medicine in the 4th quarter worth about $244,000. Hedge funds and other institutional investors own 30.86% of the company’s stock.
A number of analysts recently commented on the company. Zacks Investment Research cut Foundation Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. BidaskClub upgraded Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Cowen assumed coverage on Foundation Medicine in a research report on Thursday, February 15th. They set an “outperform” rating and a $90.00 price objective for the company. Finally, Goldman Sachs Group assumed coverage on Foundation Medicine in a research report on Monday, January 29th. They set a “neutral” rating and a $73.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $59.80.
COPYRIGHT VIOLATION WARNING: “Foundation Medicine Inc (FMI) Insider Vincent A. Miller Sells 32,008 Shares of Stock” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/02/23/foundation-medicine-inc-fmi-insider-vincent-a-miller-sells-32008-shares-of-stock.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.